Results 201 to 210 of about 455,946 (356)

A comparative study between the use of non-steroidal anti-inflammatory analgesic and antibiotics after apicectomy [PDF]

, 2001
Tahani Al–Sandook
openalex   +1 more source

Safety and pharmacokinetics of a novel potent GABA analogue crisugabalin in Chinese subjects with various degrees of renal impairment

British Journal of Clinical Pharmacology, EarlyView.
Aims Crisugabalin is a novel calcium channel α2δ subunit ligand and a highly selective oral gamma‐aminobutyric acid (GABA) analogue developed for the treatment of diabetic peripheral neuropathic pain (DPNP) and postherpetic neuralgia (PHN). This study investigated pharmacokinetic properties and safety of crisugabalin in subjects with renal impairment ...
Shibeilei Lin, Ye Wang, Chao Hu, Yanhuan Feng, Xi Tang, Ping Fu, Jia Miao   +6 more
wiley   +1 more source

Combinatorial targeting of G‐protein‐coupled bile acid receptor 1 and cysteinyl leukotriene receptor 1 reveals a mechanistic role for bile acids and leukotrienes in drug‐induced liver injury

Hepatology, EarlyView., 2022
CHIN117 is a dual cysteinyl leukotriene receptor 1 (CYSLTR1) antagonist and G‐protein‐coupled bile acid receptor 1 (GPBAR1) agonist. In the liver, GPBAR1 and CYSLTR1 are coexpressed by liver sinusoidal endothelial cells (LSECs), HSCs, circulating monocytes/macrophages, and liver resident macrophages (Kupffer cells).
Michele Biagioli, Silvia Marchianò, Cristina di Giorgio, Rosalinda Roselli, Martina Bordoni, Rachele Bellini, Bianca Fiorillo, Valentina Sepe, Bruno Catalanotti, Chiara Cassiano, Maria Chiara Monti, Eleonora Distrutti, Angela Zampella, Stefano Fiorucci   +13 more
wiley   +1 more source

Mixed-mechanism analgesics for mixed pain. [PDF]

Front Med (Lausanne)
Raffa RB.
europepmc   +1 more source

Mapping of reinforcing and analgesic effects of the mu opioid agonist Endomorphin-1 in the ventral midbrain of the rat

, 2012
Thomas C. Jhou, Shengping Xu, Mary R. Lee, Courtney L. Gallen, Satoshi Ikemoto   +4 more
openalex   +2 more sources

The persistence of chronic opioid use in patients with inflammatory bowel disease—A nationwide cohort study

British Journal of Clinical Pharmacology, EarlyView.
Aims Pain is common in patients with Crohn's disease (CD) and ulcerative colitis (UC), and a substantial proportion develop chronic opioid use (COU). We examined the persistence of COU over time and identified factors predicting persistent use. Methods This nationwide Danish cohort study included patients with an initial period of COU (definition: ≥3 ...
Bente Mertz Nørgård, Caroline Theilgaard Thorarinsson, Jan Nielsen, Mette Louise Andersen, Jens Kjeldsen, Torben Knudsen, Rahul S. Dalal   +6 more
wiley   +1 more source

Comparing analgesic efficacy of different regional blocks after total hip arthroplasty. [PDF]

J Orthop Surg Res
Wang DF, Lin YB, Xue FS.
europepmc   +1 more source

Opioid analgesics: Is it time for risk stratification prior to use? – ADDENDUM [PDF]

, 2018
Maureen A. Allen
openalex   +1 more source

Human vs. artificial intelligence: Physicians outperform ChatGPT in real‐world pharmacotherapy counselling

British Journal of Clinical Pharmacology, EarlyView.
Aims To assess the utility of the artificial intelligence (AI) chatbot ChatGPT (openly available version 3.5) in responding to real‐world pharmacotherapeutic queries from healthcare professionals. Methods Three independent and blinded evaluators with different levels of medical expertise and professional experience (beginner, advanced, and expert ...
Benjamin Krichevsky, Stefan Engeli, Stefanie M. Bode‐Böger, Felix Koop, Martin Schulze Westhoff, Sebastian Schröder, Carsten Schumacher, Thorben Pape, Dirk O. Stichtenoth, Johannes Heck   +9 more
wiley   +1 more source

Clinical effectiveness and treatment satisfaction between two triple‐therapy regimens in treating neuropathic pain: A real‐world data

Ibrain, EarlyView., 2023
This study compared the clinical effectiveness and treatment satisfaction of Pregabalin and Gabapentin triple therapy for neuropathic pain in a real‐world setting. The primary outcome measured the reduction in mean Self‐Administered Leeds Assessment of Neuropathic Symptoms and Signs pain score value from baseline to 12 weeks posttreatment.
Nithya Raju, Samyuktha Villavan, Saranya Ravi, Roja Murugesan, Panneerselvam Theivendren, Vennila Jaganathan, Redlin Jani Rajan, Krupanidhi Karunanithi   +7 more
wiley   +1 more source